Laboratory safety of dupilumab in moderate‐to‐severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS)

BACKGROUND: Dupilumab [a monoclonal antibody blocking the shared receptor subunit for interleukin (IL)‐4 and IL‐13] is approved for patients aged ≥ 12 years with inadequately controlled, moderate‐to‐severe atopic dermatitis (AD). Dupilumab trials of up to 52 weeks demonstrated efficacy and a favoura...

Descripción completa

Detalles Bibliográficos
Autores principales: Wollenberg, A., Beck, L.A., Blauvelt, A., Simpson, E.L., Chen, Z., Chen, Q., Shumel, B., Khokhar, F.A., Hultsch, T., Rizova, E., Rossi, A.B., Graham, N.M.H., Pirozzi, G., Lu, Y., Ardeleanu, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317598/
https://www.ncbi.nlm.nih.gov/pubmed/31407311
http://dx.doi.org/10.1111/bjd.18434

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317598/
https://www.ncbi.nlm.nih.gov/pubmed/31407311
http://dx.doi.org/10.1111/bjd.18434

Ejemplares similares